AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04822220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatigue Self-management Programme
Description: Fatigue Self-management Programme
Study NCT04959370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: internal fixation implantation of dynamic hip screw
Description: Dynamic hip screws (DHS) are a femoral head-sparing orthopedic device used to treat femoral neck fractures.
Study NCT04959370 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: internal fixation implantation of cannulated compression screw
Description: Cannulated Screw is designed to provide a minimally invasive method of anatomical fixation.
Study NCT04228042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib
Description: Given PO
Study NCT04228042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04228042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04228042 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo surgery
Study NCT03346876 — intervention group
Intervention type: PROCEDURE
Intervention: Nuss surgery
Description: surgical correction for pectus excacatum
Study NCT03819153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants are to inject semaglutide with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject semaglutide under their skin. Participants will inject semaglutide 1 time a week on the same day of the week. Participants' dose of semaglutide will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.
Study NCT03819153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Participants are to inject placebo (semaglutide) with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject placebo (semaglutide) under their skin. Participants will inject placebo (semaglutide) 1 time a week on the same day of the week. Participants' dose of placebo (semaglutide) will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.
Study NCT04313881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously
Study NCT04313881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azacitidine
Description: Administered either subcutaneously (SC) or intravenously (IV) according to region-specific drug labeling
Study NCT04313881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered either subcutaneously (SC) or intravenously (IV) according to region-specific drug labeling
Study NCT04313881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match magrolimab administered intravenously
Study NCT00005076 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Study NCT00005076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT00736372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PX-12
Description: Intravenous infusion, dose escalation, infused over a 72 hour period on days 1, 2 and 3 of a 21-day cycle until progression or development of unacceptable toxicity
Study NCT00727272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinine Sulfate Capsules 324 mg
Description: One 324 mg capsule administered after an overnight fast of at least 10 hours.
Study NCT00727272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinine Sulphate Tablets 300 mg
Description: One 300 mg tablet administered after an overnight fast of at least 10 hours.
Study NCT00727272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinine Sulfate Capsules 324 mg
Description: One 324 mg capsule administered thirty minutes after the initiation of a standardized, high-fat breakfast.
Study NCT02243553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir capsule
Study NCT02243553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir solution
Study NCT02243553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir capsule
Study NCT02243553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Study NCT04089332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Tests
Description: A battery of cognitive tests will be completed by the subject.
Study NCT01366144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT01366144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01366144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT01366144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01366144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study NCT02445781 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucose clamp
Description: Different levels of hypoglycemia
Study NCT01948882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESS505 (BAY1454033)
Study NCT03549728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: In group A, at the day of oocyte retrieval, after oocytes collection, 30 mU (300 mcg/0.5 ml) of G-CSF (NeupogenTM, Filgastrim, Amgen Inc., Thousand Oaks, CA, USA) was administered by slow transcervical intrauterine infusion with IUI catheter (AINSEGREY, RIMOS, Italy). In controls, normal saline was used for intrauterine infusion instead of G-CSF.
Study NCT03549728 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intrauterine infusion of normal saline
Description: In group B (controls), normal saline will be used for intrauterine infusion instead of granulocyte colony-stimulating factor on the day of oocyte retrieval.
Study NCT01063426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Atorvastatin+enoxaparin
Description: High dose atorvastatin 80mg/day for 7days after index surgery (total knee replacement arthroplasty, TKRA). At the same time Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered.
Study NCT01063426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin 40mg SQ/day 12hr before TKRA and on day 1 to day7 after TKRA should be administered.
Study NCT00529620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulfalene-pyrimethamine plus amodiaquine
Description: Monthly treatments during the malaria transmission season
Study NCT00529620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dihydroartemisinin plus piperaquine
Description: Monthly treatments during the transmission season
Study NCT00529620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulfadoxine pyrimethamine plus piperaquine
Description: Monthly treatments during the malaria transmission season
Study NCT02971683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept subcutaneous
Description: Specified dose of Abatacept subcutaneous on specified days
Study NCT00343044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan administered days 1, 8, and 15 of each 28 day cycle. Dose was 4 mg/m2 administered IV.
Study NCT00343044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: bevacizumab administered IV 10 mg/kg, days 1 and 15 of 28 day cycle.
Study NCT02575326 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Control
Description: Teens in the control group will receive standard or usual care as provided by their physician.
Study NCT02575326 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: a provider administered, tailored discussion guide
Description: Teens in the intervention group will receive a provider administered, tailored discussion guide based on motivational interviewing techniques.
Study NCT00940615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: , participants assigned to the exercise treatment group of the proposed study will participate in an aerobic exercise regimen of brisk walking on a treadmill for a 60 minute interval, three times a week
Study NCT00940615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stretching/toning
Description: Individuals in the control group will participate in a low intensity stretching and toning session for 60 minutes, three times a week
Study NCT03293992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.01% RO7058584
Description: Once daily morning administration for 7 days
Study NCT03293992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% RO7058584
Description: Once daily morning administration for 7 days
Study NCT03293992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% RO7058584
Description: Once daily morning administration for 7 days
Study NCT03293992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Once daily morning administration for 7 days
Study NCT03293992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Description: Once daily morning or evening dosing
Study NCT00179660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Capsules for oral administration.
Study NCT02912975 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mirror treatment
Description: The mirror treatment: The patient sits on a chair, both knees in 90 degrees flexion, both lower limbs undressed, and places a mirror of 100 cm x 25 cm along the trans-tibial amputation stump so that the uninjured limb is reflected in the mirror while the amputation stump can not be seen by the patient. The patient then performs slow repeated movements of the foot from neutral position into maximum flexion while closely observing the reflected image of the uninjured limb - the illusion of a limb regained - in the mirror. The procedure goes on uninterrupted for five minutes in the morning and in the evening in the home of the study patient.
Study NCT02243553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin sodium
Study NCT02243553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K
Study NCT02243553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Study NCT02243553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan hydrobromide
Study NCT02243553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam injection
Study NCT02243553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam oral solution
Study NCT02243553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin tablet
Study NCT02243553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin injection
Study NCT01988246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Patients will be assigned to treatment with 2 mg intravitreal Aflibercept injection (0.05 mL or 50 microliters) administered at the time of surgery (post cataract excision) or sham injection.
Study NCT01988246 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham injection. No actual injection. No medication is used.
Study NCT00185185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Study NCT00185185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Study NCT00185185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: tablets
Study NCT00185185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: tablets
Study NCT00185185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil
Description: tablets
Study NCT00185185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atenolol
Description: tablets
Study NCT04385953 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care
Study NCT00607555 — intervention group
Intervention type: DEVICE
Intervention: Insertion of specialized feeding tube for monitoring of EAdi
Description: The specialized feeding tube will be inserted into the esophagus and positioned at the level of the crural diaphragm. EAdi will be measured with miniaturized coated stainless steel electrodes mounted on the feeding tube. The tube is connected to a monitor where EAdi will be recorded continuously throughout the entire study period
Study NCT03378167 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MICROBIOTA
Description: Fecal microbiota enema (RBX2660) infused via colonoscope x 1 + oral microbiota capsules (RBX7455) x 6 weeks. The fecal microbiota enema (RBX2660) prepared by Rebiotix has received Health Canada Clinical Trials Application (CTA), and U.S. Food and Drug Administration Investigational New Drug Application (IND) approval for clinical trials in patients with recurrent Clostridium difficile infection, and pediatric inflammatory bowel disease. The human-derived fecal oral microbiota capsule (RBX7455) has received U.S. Food and Drug Administration Investigational New Drug Application (IND) approval for clinical trials in patients with recurrent Clostridium difficile infection.
Study NCT03378167 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo enema (Normal Saline) infused via colonoscope x 1 + oral placebo capsules (dextrose-containing capsules) x 6 weeks.~NOTE: Patients randomized to the control group will be given the option of receiving open-label treatment, with the intervention therapy, either: upon completion of the trial, or if they are removed from the trial due to disease exacerbation or other adverse event, at the discretion of their primary gastroenterologist.
Study NCT01266096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET scan with 124I-cRGDY-PEG-dots
Description: Five (5) patients with newly diagnosed or recurrent melanoma, and 18 malignant brain tumor patients (surgical (n=13) or non-surgical candidates (n=5)). Patients with either primary or metastatic brain tumors, will be i.v. injected with approximately 5 mCi (3.4-6.7 nanomoles) of 124I-cRGDY-PEG-dots (specific activity range 750.0 - 1450 mCi/mol) and undergo the microdosing study for purposes of collecting pharmacokinetic and dosimetry data. All studies will be performed using a dedicated scanner, which integrates a dedicated PET scanner and a spiral CT with proprietary fusion software.
Study NCT02971683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of Abatacept subcutaneous
Study NCT03521960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buspirone oral capsule
Description: 15 milligrams, three times daily
Study NCT03521960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 0 milligrams (placebo), three times daily
Study NCT04221451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venglustat GZ402671
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT04221451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT01328574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105
Description: 15 mg/kg intravenously
Study NCT03498612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03498612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02147548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etifoxine
Study NCT02147548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lorazepam
Study NCT02147548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02459873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer games to assess change in executive function skills
Description: Children get access to computer games for 10 weeks for an hour each week.
Study NCT02459873 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer games to assess change in executive function skills
Description: Children get access to computer games for 10 weeks for an hour each week.
Study NCT01850225 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auditory brainstem implant
Study NCT03963726 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiotherapy
Description: The liver metastases were treated with Cyberknife stereotactic radiotherapy.Using multimodal image fusion to outline the target area.According to the volume, location, organ function and other factors, the dosage of radiotherapy was determined. The range of BED value of radiotherapy was 90-120 when the distance between the tumor and gastrointestinal tract was more than 5 mm (alpha/beta=10) and 70-90 when the distance between the tumor and gastrointestinal tract was less than 5 mm (alpha/beta=10).
Study NCT03963726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: microwave alabation
Description: The colorectal cancer patients with liver metastases will receive microwave ablation.3D printing template was used to assist microwave ablation.For those whose lesions are directly smaller than 5.0cm, the ablation time is about 10 min and 15 min, and the ablation time is more than 15min in patients larger than 5.0cm.
Study NCT02967185 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Therapy for Insomnia
Description: Treatment will consist of 4 weekly, 1 hour sessions and will be conducted by a trained graduate assistant on an individual basis. Treatment components will include education about aging and sleep. It will also include instruction in techniques designed to: (a) promote good sleep habits, (b) restrict the use of the bed and bedroom to sleep and sleep-conducive activities, (c) modify bed and wake times to better match the participants sleep needs, and (d) promote relaxation. Daily home practice of these techniques will be encouraged. Participants will maintain logs of their home practice sessions and will continue to record their daily sleep habits throughout treatment.
Study NCT01930370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicarbonate hemodialysis solution (low concentration)
Description: One-week experimental session (3 dialysis treatments) with low dialysate bicarbonate (28 mmol/L)
Study NCT01930370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicarbonate hemodialysis solution (high concentration)
Description: One-week experimental session with high dialysate bicarbonate (38 mmol/L)
Study NCT01002326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy
Description: 20 sessions of Cognitive-Behavioral Therapy
Study NCT03664830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Up to two subcutaneous injections of plerixafor (starting dose level: 240 µg/kg/dose)
Study NCT04393441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 011516X (New Artificial Tear Formulation)
Description: Topical eye drops
Study NCT04393441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane Ultra Multidose
Description: Topical eye drops
Study NCT04393441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REFRESH PLUS®
Description: Topical eye drops
Study NCT04393441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REFRESH PLUS®
Description: Topical eye drops
Study NCT01817179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FES neuroprosthesis to dorsiflexors on affected leg
Study NCT03332524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP160412 Ibuprofen 400 mg and Chlorpheniramine maleate 4 mg
Description: 2 Ibuprofen and capsules Chlorpheniramine maleate 3 time per day for 72 hours
Study NCT03332524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2 capsules Ibuprofen and 1 placebo
Description: Ibuprofen and placebo
Study NCT03332524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: capsule Chlorpheniramine 4mg and 1 Placebo
Description: Chlorpheniramine 4mg and one capsule Placebo 3/72days
Study NCT01235208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Dr. Fedon Lindbergs Vektcoach Treatment
Description: Diet and lifestyle treatment
Study NCT01747213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNC
Study NCT01747213 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose fiber